Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Imatinib Drug Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Tablets
  • 1.3.3 Capsules
• 1.4 Market Segment by Application
  • 1.4.1 Global Imatinib Drug Market Share by Application (2019-2025)
  • 1.4.2 Chronic myelogenous leukemia
  • 1.4.3 Gastrointestinal stromal tumors
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Imatinib Drug Market Size
  • 2.1.1 Global Imatinib Drug Revenue 2014-2025
  • 2.1.2 Global Imatinib Drug Sales 2014-2025
• 2.2 Imatinib Drug Growth Rate by Regions
  • 2.2.1 Global Imatinib Drug Sales by Regions 2014-2019
  • 2.2.2 Global Imatinib Drug Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Imatinib Drug Sales by Manufacturers
  • 3.1.1 Imatinib Drug Sales by Manufacturers 2014-2019
  • 3.1.2 Imatinib Drug Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Imatinib Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Imatinib Drug Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Imatinib Drug Market Concentration Ratio (CR5 and HHI)
• 3.3 Imatinib Drug Price by Manufacturers
• 3.4 Key Manufacturers Imatinib Drug Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Imatinib Drug Market
• 3.6 Key Manufacturers Imatinib Drug Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Tablets Sales and Revenue (2014-2019)
  • 4.1.2 Capsules Sales and Revenue (2014-2019)
• 4.2 Global Imatinib Drug Sales Market Share by Type
• 4.3 Global Imatinib Drug Revenue Market Share by Type
• 4.4 Imatinib Drug Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Imatinib Drug Sales by Application

6 United States

• 6.1 United States Imatinib Drug Breakdown Data by Company
• 6.2 United States Imatinib Drug Breakdown Data by Type
• 6.3 United States Imatinib Drug Breakdown Data by Application

7 European Union

• 7.1 European Union Imatinib Drug Breakdown Data by Company
• 7.2 European Union Imatinib Drug Breakdown Data by Type
• 7.3 European Union Imatinib Drug Breakdown Data by Application

8 China

• 8.1 China Imatinib Drug Breakdown Data by Company
• 8.2 China Imatinib Drug Breakdown Data by Type
• 8.3 China Imatinib Drug Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Imatinib Drug Breakdown Data by Company
• 9.2 Rest of World Imatinib Drug Breakdown Data by Type
• 9.3 Rest of World Imatinib Drug Breakdown Data by Application
• 9.4 Rest of World Imatinib Drug Breakdown Data by Countries
  • 9.4.1 Rest of World Imatinib Drug Sales by Countries
  • 9.4.2 Rest of World Imatinib Drug Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Novartis
  • 10.1.1 Novartis Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.1.4 Imatinib Drug Product Introduction
  • 10.1.5 Novartis Recent Development
• 10.2 Glenmark Pharmaceuticals Ltd.
  • 10.2.1 Glenmark Pharmaceuticals Ltd. Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.2.4 Imatinib Drug Product Introduction
  • 10.2.5 Glenmark Pharmaceuticals Ltd. Recent Development
• 10.3 Sun Pharmaceuticals
  • 10.3.1 Sun Pharmaceuticals Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.3.4 Imatinib Drug Product Introduction
  • 10.3.5 Sun Pharmaceuticals Recent Development
• 10.4 Actavis Generics
  • 10.4.1 Actavis Generics Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.4.4 Imatinib Drug Product Introduction
  • 10.4.5 Actavis Generics Recent Development
• 10.5 Dr. Reddy's Laboratories
  • 10.5.1 Dr. Reddy's Laboratories Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.5.4 Imatinib Drug Product Introduction
  • 10.5.5 Dr. Reddy's Laboratories Recent Development
• 10.6 Teva Pharmaceutical Industries Ltd.
  • 10.6.1 Teva Pharmaceutical Industries Ltd. Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.6.4 Imatinib Drug Product Introduction
  • 10.6.5 Teva Pharmaceutical Industries Ltd. Recent Development
• 10.7 Sanofi S.A.
  • 10.7.1 Sanofi S.A. Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.7.4 Imatinib Drug Product Introduction
  • 10.7.5 Sanofi S.A. Recent Development
• 10.8 Cipla Inc.
  • 10.8.1 Cipla Inc. Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.8.4 Imatinib Drug Product Introduction
  • 10.8.5 Cipla Inc. Recent Development
• 10.9 Apotex Inc.
  • 10.9.1 Apotex Inc. Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.9.4 Imatinib Drug Product Introduction
  • 10.9.5 Apotex Inc. Recent Development
• 10.10 Mylan Pharms Inc.
  • 10.10.1 Mylan Pharms Inc. Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Imatinib Drug
  • 10.10.4 Imatinib Drug Product Introduction
  • 10.10.5 Mylan Pharms Inc. Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Imatinib Drug Sales Channels
  • 11.2.2 Imatinib Drug Distributors
• 11.3 Imatinib Drug Customers

12 Market Forecast

• 12.1 Global Imatinib Drug Sales and Revenue Forecast 2019-2025
• 12.2 Global Imatinib Drug Sales Forecast by Type
• 12.3 Global Imatinib Drug Sales Forecast by Application
• 12.4 Imatinib Drug Forecast by Regions
  • 12.4.1 Global Imatinib Drug Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Imatinib Drug Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the imatinib drug market. Furthermore, rise in healthcare expenditure and increase in awareness of cancer by government and private organizations are anticipated to boost the market growth.
In 2019, the market size of Imatinib Drug is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Imatinib Drug.

This report studies the global market size of Imatinib Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Imatinib Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.

Market Segment by Product Type
Tablets
Capsules

Market Segment by Application
Chronic myelogenous leukemia
Gastrointestinal stromal tumors
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Imatinib Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Imatinib Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Imatinib Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025